Trials / Recruiting
RecruitingNCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Conditions
- Breast Cancer
- Gastric Cancer
- Esophageal Cancer
- Gastroesophageal Cancer
- Colorectal Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer
- Ovarian Cancer
- Urothelial Carcinoma
- Salivary Gland Cancer
- Pancreatic Cancer
- HER-2 Protein Overexpression
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanidatamab | Administered by intravenous (IV) infusion |
Timeline
- Start date
- 2025-01-14
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2024-11-19
- Last updated
- 2026-04-09
Locations
21 sites across 2 countries: United States, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06695845. Inclusion in this directory is not an endorsement.